Pelthos Therapeutics Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 |
|---|---|---|---|---|
| Revenue | $16.8M | $0 | — | — |
| Operating income | -$32.4M | -$7.6M | -$6.9M | -$2.3M |
| Operating expenses | — | $7.6M | $6.9M | $2.3M |
| Cost of revenue | $4.0M | $0 | — | — |
| Cash from operations | -$22.6M | -$5.8M | -$981,031 | -$1.6M |
| Capital expenditure | $99,000 | $0 | — | — |
| Free cash flow | -$22.7M | -$5.8M | — | — |
| Share repurchases | $0 | $75,000 | — | — |
| Impairments | $285,000 | $0 | — | — |
| Total assets | $130.4M | $1.4M | $96,391 | $55,074 |
| Total liabilities | $91.5M | $4.1M | $6.5M | $3.8M |
Shares outstanding 3.5M · Free float 39.6%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.